Local bone interaction between renin-angiotensin system and kallikrein-kinin system in diabetic rat. 2015

Yong Li, and Guang-Si Shen, and Chen Yu, and Guang-Fei Li, and Jun-Kang Shen, and You-Jia Xu, and Jian-Ping Gong
Department of Radiology, The Second Affiliated Hospital of Soochow University 1055 Sanxiang Road, Suzhou, China.

OBJECTIVE This study was performed to investigate bone deteriorations and the involvement of skeletal renin-angiotensin system (RAS) and kallikrein-kinin system (KKS) of male rat in response to the hyperglycemia. METHODS The biomarkers in serum and urine were measured by ELISA kit, and tibias were taken for the measurement on gene, protein expression and histological analysis, femurs were taken for the measurement on biomechanical parameters and micro-CT. RESULTS The DM1 showed the decreased level of osteocalcin, testosterone and FGF-23, and the increased level of serum CTX as compared to those of vehicle group. The H&E staining showed remarkable bone deteriorations, including increased disconnections and separation of trabecular bone among growth plate and joint cartilage in DM1 group. Biomechanically, the maximum load, maximum stress, and strain parameter of DM1 group was significantly lower than control group. Type 1 diabetic mice displayed bone loss shown the reduction of bone volume/total volume, trabecular number, trabecular thickness and bone mineral density. The STZ injection significantly up-regulated mRNA expression of AT1R, AGT, renin, renin-receptor, and ACE, and the expression of AT2R, B1R and B2R were down-regulated in tibia of rat in hyperglycemia group. The protein expression of renin, ACE and Ang II were significantly up-regulated, and AT2R, B1R and B2R were down-regulated in DM1 group. CONCLUSIONS The treatment of hyperglycemia was detrimental to bone as compared to the vehicle group, and the underlying mechanism was mediated, at least partially, through down-regulation of KSS activity and up-regulation of RAS activity in local bone.

UI MeSH Term Description Entries
D008297 Male Males
D012084 Renin-Angiotensin System A BLOOD PRESSURE regulating system of interacting components that include RENIN; ANGIOTENSINOGEN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; and angiotensinase. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I. Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an extremely powerful vasoconstrictor. Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure. In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney. Angiotensin-converting enzyme also breaks down BRADYKININ, a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM. Renin-Angiotensin-Aldosterone System,Renin Angiotensin Aldosterone System,Renin Angiotensin System,System, Renin-Angiotensin,System, Renin-Angiotensin-Aldosterone
D001842 Bone and Bones A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principal cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX. Bone Tissue,Bone and Bone,Bone,Bones,Bones and Bone,Bones and Bone Tissue,Bony Apophyses,Bony Apophysis,Condyle,Apophyses, Bony,Apophysis, Bony,Bone Tissues,Condyles,Tissue, Bone,Tissues, Bone
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D000089703 Fibroblast Growth Factor-23 A specific fibrobroblast growth factor that is primarily synthesized by OSTEOCYTES and OSTEOBLASTS. It is involved in regulating phosphate homeostasis and renal phosphate excretion. Fibroblast Growth Factor 23
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015153 Blotting, Western Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes. Immunoblotting, Western,Western Blotting,Western Immunoblotting,Blot, Western,Immunoblot, Western,Western Blot,Western Immunoblot,Blots, Western,Blottings, Western,Immunoblots, Western,Immunoblottings, Western,Western Blots,Western Blottings,Western Immunoblots,Western Immunoblottings
D016234 Kallikrein-Kinin System A system of metabolic interactions by products produced in the distal nephron of the KIDNEY. These products include KALLIKREIN; KININS; KININASE I; KININASE II; and ENKEPHALINASE. This system participates in the control of renal functions. It interacts with the RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM to regulate BLOOD PRESSURE, generation of PROSTAGLANDINS, release of VASOPRESSINS, and WATER-ELECTROLYTE BALANCE. Kallikrein Kinin System,Kallikrein-Kinin Systems,Systems, Kallikrein-Kinin

Related Publications

Yong Li, and Guang-Si Shen, and Chen Yu, and Guang-Fei Li, and Jun-Kang Shen, and You-Jia Xu, and Jian-Ping Gong
June 1984, Kidney international,
Yong Li, and Guang-Si Shen, and Chen Yu, and Guang-Fei Li, and Jun-Kang Shen, and You-Jia Xu, and Jian-Ping Gong
April 2002, The Journal of clinical investigation,
Yong Li, and Guang-Si Shen, and Chen Yu, and Guang-Fei Li, and Jun-Kang Shen, and You-Jia Xu, and Jian-Ping Gong
May 1978, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
Yong Li, and Guang-Si Shen, and Chen Yu, and Guang-Fei Li, and Jun-Kang Shen, and You-Jia Xu, and Jian-Ping Gong
January 1986, Advances in experimental medicine and biology,
Yong Li, and Guang-Si Shen, and Chen Yu, and Guang-Fei Li, and Jun-Kang Shen, and You-Jia Xu, and Jian-Ping Gong
January 2016, Journal of diabetes and its complications,
Yong Li, and Guang-Si Shen, and Chen Yu, and Guang-Fei Li, and Jun-Kang Shen, and You-Jia Xu, and Jian-Ping Gong
July 2003, American journal of physiology. Regulatory, integrative and comparative physiology,
Yong Li, and Guang-Si Shen, and Chen Yu, and Guang-Fei Li, and Jun-Kang Shen, and You-Jia Xu, and Jian-Ping Gong
August 1983, La Clinica terapeutica,
Yong Li, and Guang-Si Shen, and Chen Yu, and Guang-Fei Li, and Jun-Kang Shen, and You-Jia Xu, and Jian-Ping Gong
March 2005, Nihon rinsho. Japanese journal of clinical medicine,
Yong Li, and Guang-Si Shen, and Chen Yu, and Guang-Fei Li, and Jun-Kang Shen, and You-Jia Xu, and Jian-Ping Gong
June 2003, The international journal of biochemistry & cell biology,
Yong Li, and Guang-Si Shen, and Chen Yu, and Guang-Fei Li, and Jun-Kang Shen, and You-Jia Xu, and Jian-Ping Gong
January 1983, Nihon Jinzo Gakkai shi,
Copied contents to your clipboard!